Table 3.

Top 10 gene pathways (ranked by p-value) altered in L3 or L5 pyramidal cells for SZ^**.

Name of pathway	Number of genes in pathway	L3		L5
		DEGs in pathway*	p-value	DEGs in pathway*	p-value
Oxidative phosphorylation	95	41 (43.2%)	< 10-24	27 (28.4%)	< 10-10
Mitochondrial dysfunction	155	49 (31.6%)	< 10-22	32 (20.6%)	< 10-8
EIF2 signaling	182	38 (20.9%)	< 10-10	31 (17%)	< 10-6
Protein Ubiquitination Pathway	254	34 (13.4%)	< 10-5
Regulation of eIF4 and p70S6K Signaling	151	21 (13.9%)	<0.001	24 (15.9%)	< 10-5
mTOR Signaling	193	24 (12.4%)	<0.001	25 (13%)	<0.001
CDK5 Signaling	98			15 (15.3%)	<0.001
Pyrimidine Deoxyribonucleotides De Novo Biosynthesis I	23	6 (26.1%)	<0.01
Pyrimidine Ribonucleotides Interconversion	30	6 (20%)	<0.01
Gluconeogenesis I	24			6 (25%)	<0.01
Cdc42 Signaling	121			15 (12.4%)	<0.01
Endoplasmic Reticulum Stress Pathway	21			5 (23.8%)	<0.01
TCA Cycle II (Eukaryotic)	23	5 (21.7%)	0.010	6 (26.1%)	<0.01
Pyrimidine Ribonucleotides De Novo Biosynthesis	32	6 (18.8%)	0.011

^*Number and % of differentially expressed genes (DEGs) in each pathway.

^**No significantly altered pathways were detected in either layer for subjects with bipolar or major depressive disorder.